News

Healthcare — latest

  1. HealthcareAMGN▲ +0.75%

    Amgen Inc (AMGN) Adds 0.75% to Close at $447.95, Near 52-Week High

    Amgen Inc (AMGN) common stock rose 0.75% to close at $447.95, positioning the biotechnology company at 98.1% of its 52-week range. The stock has returned 51.81% over the past year and trades 19.47% above its 200-day average. Last quarter Amgen reported EPS of 6.29 against a 5.73 estimate, a beat with a 9.81% surprise.

  2. HealthcareBMY▼ -0.10%

    Bristol-Myers Squibb Co (BMY) Slips 0.10% to $61.55 Despite Annual Gain

    Bristol-Myers Squibb Co (BMY) common stock declined 0.10% to close at $61.55, despite a one-year return of 40.57% for the pharmaceuticals company. The stock sits at 72.9% of its 52-week range and trades 2.96% above its 200-day average. Last quarter Bristol-Myers Squibb Co (BMY) reported EPS of 2.04 against a 1.60 estimate, a beat with a 27.20% surprise.

  3. HealthcareTMO▲ +1.95%

    Thermo Fisher Scientific rises 1.95% as activist campaign at Bio-Rad draws valuation comparisons

    Thermo Fisher Scientific Inc (TMO) rose 1.95% to $698.27 during the session. An investor thesis published on One Idea Per Day's Substack highlighted Bio-Rad Laboratories' valuation discount relative to peers including Thermo Fisher Scientific Inc (TMO), as activist investor Elliott pressures the company. The stock is trading near the top of its 52-week range at 97.2% of the band.

  4. HealthcareISRG▼ -1.30%

    Intuitive Surgical shares fall 1.3% as analysts maintain bullish stance

    Intuitive Surgical Inc (ISRG) was trading at $445.77, down 1.30% during the session. The average brokerage recommendation for the medical device maker stands at the equivalent of Buy, according to a Yahoo Finance analysis. The stock has declined 18.08% over the past year and sits 42.6% of the way through its 52-week range of $328.57 to $603.88.

  5. HealthcareABT▼ -1.39%

    Abbott Laboratories stock falls 1.39% as analysts maintain positive ratings

    Abbott Laboratories (ABT) fell 1.39% to $103.42 during the regular session. Wall Street analysts continue to issue optimistic recommendations on the health care company, according to average brokerage ratings. The stock sits at 42.8% of its 52-week range of $81.97 to $132.03.

  6. HealthcareGILD▼ -0.73%

    Gilead Sciences secures Canadian reimbursement agreement for PBC treatment seladelpar

    Gilead Sciences, Inc (GILD) fell 0.73% to $157.53 during the regular session. The biotechnology company announced it has concluded negotiations with the pan-Canadian Pharmaceutical Alliance for public reimbursement of LYVDELZI (seladelpar), a treatment for primary biliary cholangitis. The stock has gained 31.43% over the past year and sits at 93.6% of its 52-week range.

  7. HealthcareJNJ▲ +0.94%

    Johnson & Johnson rises 0.94% as company schedules December investor event

    Johnson & Johnson (JNJ) common stock rose 0.94% to close at $266.30. The pharmaceutical company announced it will hold an investor event on December 8th, 2026, where executives will review its Innovative Medicine and MedTech divisions and discuss long-term growth strategy. The stock is trading 84.7% of the way through its 52-week range of $184.66 to $281.07.

  8. HealthcareREGN▲ +0.33%

    Regeneron Pharmaceuticals shares rise 0.33% as Libtayo shows sustained survival benefit in four-year trial

    Regeneron Pharmaceuticals Inc (REGN) closed up 0.33% at $807.67. The company reported nearly four-year Phase 3 C-POST trial data showing sustained overall survival and disease-free survival benefit for Libtayo in high-risk cutaneous squamous cell carcinoma patients following surgery. The stock has returned 40.30% over the past year.

  9. HealthcareBMY▲ +0.21%

    Bristol-Myers Squibb edges up 0.21% on late-stage cancer drug trial results

    Bristol-Myers Squibb Co (BMY) closed 0.21% higher at $61.61. The company's cancer drug, developed with its Chinese partner, doubled progression-free survival time in a late-stage clinical trial. The stock has gained 40.57% over the past year.

  10. HealthcarePFE▼ -0.80%

    Pfizer Inc falls 0.80% as valuation concerns emerge after 30% gain

    Pfizer Inc (PFE) closed down 0.80% at $29.79 amid questions over whether its share price aligns with earnings support. The stock has returned 21.48% over the past year and trades at 90.5% of its 52-week range. Its RSI of 78.3 suggests the stock is trading in overbought territory.

  11. HealthcareMRK▼ -3.21%

    Merck & Co shares fall 3.21% as endometrial cancer trial data emerges

    Merck & Co Inc (MRK) closed down 3.21% at $140.61. The pharmaceutical company's Sac-TMT treatment showed median overall survival of 19 months versus 12.1 months for chemotherapy in a 776-patient Phase 3 endometrial cancer trial, with FDA decision expected by June 2027. The stock has gained 65.81% over the past year.

  12. HealthcareDXCM▲ +0.81%

    Dexcom Shares Gain 0.81% Ahead of Third-Quarter Earnings Release

    Dexcom Inc (DXCM) common stock rose 0.81% to $78.57 ahead of its Q3 FY2026 earnings report. The health care company is expected to benefit from continuous glucose monitoring adoption, uptake of its G7 15 Day product, and expanded reimbursement coverage. Volume reached 1.37 times the 20-day average, though the stock remains 10.23% below its 50-day moving average.

  13. HealthcareTMO▲ +0.57%

    Thermo Fisher gains 0.57% as industry report forecasts DNA sequencing market to reach $15.22B by 2030

    Thermo Fisher Scientific Inc (TMO) rose 0.57% to $677.67 at 13:15 ET. ResearchAndMarkets.com published a report projecting the DNA sequencing in drug discovery market will reach $15.22 billion by 2030, growing at a 12.5% CAGR, naming Thermo Fisher Scientific Inc (TMO) among key players alongside Illumina, QIAGEN, and Oxford Nanopore. The life sciences tools company has gained 43.45% over six months.

  14. HealthcareMRNA▼ -1.79%

    Moderna shares fall 1.79% amid revised outlook for Merck cancer vaccine partnership

    Moderna Inc (MRNA) was trading at $196.51, down 1.79%, after earlier dropping as much as 10% during the session. The biotechnology company faced tempered expectations for INT, its cancer vaccine developed in partnership with Merck. The stock has gained 645.25% over the past year.

  15. HealthcareAMGN▲ +0.39%

    Amgen gains 0.39% as investment committee highlights stock

    Amgen Inc (AMGN) rose 0.39% to $440.95 during the regular session. The biotechnology company was discussed by an investment committee as a stock on the move. Amgen is trading at 93.8% of its 52-week range and has returned 48.41% over the past year.

  16. HealthcareABT▲ +1.16%

    Abbott Laboratories introduces genomic cancer test for residual disease monitoring

    Abbott Laboratories (ABT) rose 1.16% to $104.91 during the regular session. The company launched Oncodetect, a whole-genome sequencing test designed to detect molecular residual disease and trace amounts of cancer during and after treatment. The stock trades 45.8% into its 52-week range of $81.97 to $132.03.

  17. HealthcareBMY▼ -0.33%

    Bristol-Myers Squibb dividend quality examined in income investor screen

    Bristol-Myers Squibb Co (BMY) fell 0.33% to $61.28 during the regular session. ChartMill analyzed the company as a case study in its Best Dividend Stocks screen, weighing high yield against profitability and financial health. The stock has returned 38.50% over the past year.

  18. HealthcareISRG▲ +1.12%

    Intuitive Surgical shares gain 1.12% as valuation debate continues

    Intuitive Surgical Inc (ISRG) was trading at $457.35, up 1.12% during the session. The health care company's stock sits 46.8% into its 52-week range of $328.57 to $603.88. Volume ran at 1.34 times the 20-day average, while the stock has declined 14.18% over the past year.

  19. HealthcarePFE▼ -1.28%

    Pfizer Slips 1.28% Despite Trading Near Top of 52-Week Range

    Pfizer Inc (PFE) common stock fell 1.28% to $30.03. The pharmaceuticals company is positioned at 94.0% of its 52-week range of $23.62 to $30.44. Pfizer reported Q2 FY2026 EPS of 0.77 against a 0.69 estimate, an 11.37% beat.

  20. HealthcareMRK▼ -0.59%

    Merck shares slip 0.59% amid pharma sector comparison

    Merck & Co Inc (MRK) was trading at $144.42, down 0.59% during the session. The pharmaceutical company has gained 65.81% over the past year and sits at 83.3% of its 52-week range of $82.01 to $156.92. The stock's RSI (14) stands at 59.0.

  21. HealthcareGILD▲ +1.74%

    Gilead Sciences stock rises 1.74% ahead of Q3 results

    Gilead Sciences, Inc (GILD) rose 1.74% to $158.76 during the regular session. The biotechnology company is set to report third-quarter earnings for the period ended September 2026. The stock is trading at 96.2% of its 52-week range, with shares up 28.47% over the past year.

  22. HealthcareMRNA▼ -1.25%

    Moderna Inc (MRNA) Falls 1.25% as Investors Await Fed Decision

    Moderna Inc (MRNA) closed down 1.25% at $200.10. The biotechnology company's shares moved lower as investors turned their attention to the Federal Reserve's policy announcement due this week. The stock has gained 645.25% over the past year and trades 76.6% into its 52-week range of $22.28 to $254.48.

  23. HealthcarePFE▲ +1.36%

    Pfizer shares gain 1.36% to near 52-week high as dividend yield reaches 5.7%

    Pfizer Inc (PFE) rose 1.36% to $30.25, reaching 98.4% of its 52-week range and touching a new 52-week high of $30.36 during the session. The pharmaceutical company's dividend yield now stands at 5.7%, drawing attention from income-focused investors. Pfizer has gained 20.90% over the past year and trades 12.07% above its 200-day average.

  24. HealthcareABT▲ +1.93%

    Abbott Laboratories shares rise 1.93% as company announces spinoff plan alongside Q3 earnings

    Abbott Laboratories (ABT) was trading at $102.45, up 1.93%, on volume 2.45 times its 20-day average. The healthcare company reported Q3 FY2026 adjusted earnings per share of $1.42 and comparable sales growth of roughly 7%, while announcing plans to spin off a business unit. The stock trades 40.9% of the way through its 52-week range of $81.97 to $132.03.

  25. HealthcareJNJ▲ +2.05%

    Johnson & Johnson shares rise 2.05% as mixed quarterly results spark valuation debate

    Johnson & Johnson (JNJ) rose 2.05% to $263.07 during the regular session. The pharmaceutical company reported Q3 FY2026 earnings of $2.59 per share, beating the $2.56 estimate, though revenue of $25.40B missed the $25.53B consensus. The stock has returned 33.07% over the past year and trades at 81.3% of its 52-week range.

  26. HealthcareMRK▼ -2.84%

    Merck & Co shares fall 2.8% ahead of Q3 results

    Merck & Co Inc (MRK) was trading at $145.62, down 2.84%, during the regular session. Zacks Investment Research published an earnings preview noting the pharmaceutical company may not have the right combination of factors for a likely beat in its upcoming quarterly report. The stock has gained 73.63% over the past year and sits at 84.9% of its 52-week range.

  27. HealthcareABBV▼ -0.51%

    AbbVie shares dip 0.51% despite Phase 3 trial success for hidradenitis suppurativa drug

    AbbVie Inc (ABBV) fell 0.51% to $283.34 during the regular session. The biotechnology company reported that its Phase 3 INTREPID study of lutikizumab, an investigational dual-variable-domain IL-1α/1β antagonist, met its primary endpoint and eight ranked secondary endpoints in patients with moderate to severe hidradenitis suppurativa. The stock has gained 42.04% over the past six months.

  28. HealthcareUNH▲ +1.95%

    UnitedHealth Group rises 2.0% as investor interest increases

    UnitedHealth Group Inc (UNH) was trading at $425.12, up 1.95%, during the regular session. Zacks.com reported the health care company has received increased attention from users on its platform. The stock's RSI (14) stands at 80.4, and UnitedHealth reported Q3 FY2026 EPS of $4.69 against a $4.18 estimate, a beat.

  29. HealthcareBMY▼ -0.91%

    Bristol-Myers Squibb edges lower, down 0.9% in quiet session

    Bristol-Myers Squibb Co (BMY) declined 0.91% to $61.12 on volume running 0.66 times the 20-day average. The pharmaceuticals company has gained 40.22% over the past year and trades 71.2% into its 52-week band of $42.52 to $68.64.

  30. HealthcareLLY▼ -1.01%

    Eli Lilly shares slip 1.01% as pharma revenue growth draws attention

    Eli Lilly and Co (LLY) fell 1.01% to $1270.75, closing below its previous session price of $1283.66. The pharmaceutical company's revenue nearly doubled over two years, according to a Yahoo report comparing its performance with Bristol Myers Squibb. The stock has returned 57.08% over the past year and sits at 91.9% of its 52-week range.

  31. HealthcareABT▼ -1.89%

    Abbott Laboratories plans to separate nutrition unit

    Abbott Laboratories (ABT) fell 1.89% to close at $100.51 on volume 2.45 times its 20-day average. The health care company announced it will separate its nutrition business into an independent publicly traded company, citing differing investment profiles and innovation timelines. The stock has declined 22.39% over the past year.

  32. HealthcareGILD▼ -1.88%

    Gilead Sciences Falls 1.88% as BioNTech Partners on Triple-Negative Breast Cancer Trial

    Gilead Sciences, Inc (GILD) fell 1.88% to close at $153.57. BioNTech announced a clinical trial collaboration with Gilead Sciences, Inc (GILD) to evaluate pumitamig in combination with Gilead's sacituzumab govitecan in the global Phase 3 ROSETTA Breast-01 trial for metastatic triple-negative breast cancer. The stock trades at 85.1% of its 52-week range.

  33. HealthcareISRG▼ -2.26%

    Intuitive Surgical shares fall 2.3% after Q3 results

    Intuitive Surgical Inc (ISRG) closed down 2.26% at $428.12 after reporting third-quarter results. The health care company posted earnings of $3.00 per share on revenue of $3.05B, beating estimates of $2.70 and $2.96B respectively. Volume ran 2.32 times the 20-day average as the stock traded 36.2% into its 52-week range of $328.57 to $603.88.

  34. HealthcareTMO▲ +0.97%

    Thermo Fisher Scientific shares rise 0.97% following Q3 earnings beat

    Thermo Fisher Scientific Inc (TMO) closed up 0.97% at $694.02, near the top of its 52-week range at 95.7% of the band. The life sciences tools company reported third-quarter results with non-GAAP earnings per share of $6.68, beating the $6.47 estimate, and revenue of $12.14 billion, up 9.1% year on year. Volume ran 1.77 times the 20-day average as the stock traded within 8.11% of its 50-day moving average.

  35. HealthcareMRNA▲ +1.54%

    Moderna gains 1.54% after NASDAQ-100 Index addition announced

    Moderna Inc (MRNA) rose 1.54% to $245.81, reaching 96.3% of its 52-week range following the biotech company's inclusion in the NASDAQ-100 Index. The stock has delivered a 1-year return of 802.39% and a 6-month return of 342.10%. Moderna's RSI of 69.2 and position 48.40% above its 50-day average reflect strong recent momentum.

  36. HealthcareABT▼ -1.83%

    Abbott falls 1.8% after announcing nutrition unit spinoff

    Abbott Laboratories (ABT) fell 1.83% to $100.57 after the close. The company announced during its Q3 2026 earnings call that it plans to spin off its nutrition business by the end of 2027. Volume ran 1.52 times the 20-day average.

  37. HealthcareLLY▼ -1.01%

    Eli Lilly (LLY) Drops 1.01% Ahead of Q3 Results Next Week

    Eli Lilly and Co (LLY) fell 1.01% to close at $1270.75, positioned at 92.1% of its 52-week range. The pharmaceutical company reports third-quarter results in about a week; in Q2 FY2026, revenue rose 48% to $23.0 billion as volume jumped 60% while price per unit fell 13%. The stock has returned 59.89% over the past year.

  38. HealthcareJNJ▼ -0.85%

    Johnson & Johnson (JNJ) Declines 0.85% After Raising 2026 Outlook

    Johnson & Johnson (JNJ) was trading at $257.15, down 0.85%, at 15:45 ET Wednesday. The pharmaceutical company raised its 2026 forecast earlier this month, now expecting full-year sales of about $101.2B at the midpoint and slightly higher adjusted earnings per share. The stock sits at 75.2% of its 52-week range of $184.66 to $281.07.

  39. HealthcareAMGN▼ -0.14%

    Amgen (AMGN) Edges Down 0.14% After Tezspire Phase 3 Success

    Amgen Inc (AMGN) declined 0.14% to close at $438.34 on below-average volume of 0.76 times its 20-day mean. Amgen and AstraZeneca reported this week that Tezspire met both main goals in a Phase 3 trial for eosinophilic esophagitis, with benefit lasting through week 52. The stock sits at 94.5% of its 52-week range and has gained 46.90% over the past year.

  40. HealthcareTMO▲ +1.11%

    Thermo Fisher Scientific (TMO) gains 1.1% after Q3 results

    Thermo Fisher Scientific Inc (TMO) was trading up 1.11% at $694.98 as of 15:15 ET Wednesday. The life sciences tools and services company reported Q3 FY2026 results, with revenue reaching $12.14 billion and adjusted EPS rising 15%. The stock reached $705.78 during the session, matching the top of its 52-week range.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy